Mesoblast (MESO) Intangibles (2015 - 2025)
Mesoblast (MESO) posted Intangibles of $568.8 million for Q4 2025, down 0.53% sequentially from $571.8 million in Q2 2025, and down 1.06% YoY from $574.9 million in Q4 2024.
Mesoblast (MESO) Intangibles (2015 - 2025) Analysis & Trends
Mesoblast has reported Intangibles for 11 years, with the latest figure at $568.8 million in Q4 2025.
- Quarterly Intangibles fell 1.06% year-over-year to $568.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $568.8 million (down 1.06% YoY) and the FY2025 annual result came in at $571.8 million, down 0.68% from the prior year.
- Intangibles retreated to $568.8 million in Q4 2025 per MESO's latest filing, from $571.8 million in the prior quarter.
- Over five years, Intangibles peaked at $580.9 million in Q1 2021 and troughed at $568.8 million in Q4 2025.
- A 5-year average of $577.2 million and a median of $577.9 million in 2022 frame the typical range for Intangibles.
- The sharpest annual moves came in 2021 and 2025: Intangibles retreated 0.17% in 2021, then dropped 1.06% in 2025.
- Over 5 years, Intangibles stood at $579.8 million in 2021, then fell by 0.33% to $577.9 million in 2022, then slipped by 0.23% to $576.6 million in 2023, then decreased by 0.29% to $574.9 million in 2024, then fell by 1.06% to $568.8 million in 2025.
- According to Business Quant data, Intangibles over the past three periods registered $568.8 million, $571.8 million, and $574.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | 568.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 568.80 Mn |
| Jun 30, 2025 | 571.83 Mn |
| Dec 31, 2024 | 574.88 Mn |
| Jun 30, 2024 | 575.74 Mn |
| Dec 31, 2023 | 576.56 Mn |
| Jun 30, 2023 | 577.18 Mn |
| Mar 31, 2023 | 577.53 Mn |
| Dec 31, 2022 | 577.90 Mn |
| Sep 30, 2022 | 578.28 Mn |
| Jun 30, 2022 | 578.65 Mn |
| Mar 31, 2022 | 578.95 Mn |
| Dec 31, 2021 | 579.84 Mn |
| Sep 30, 2021 | 580.18 Mn |
| Jun 30, 2021 | 580.55 Mn |
| Mar 31, 2021 | 580.94 Mn |
| Dec 31, 2020 | 581.33 Mn |
| Sep 30, 2020 | 581.22 Mn |
| Jun 30, 2020 | 581.60 Mn |
| Mar 31, 2020 | 581.94 Mn |
| Dec 31, 2019 | 582.34 Mn |